天津医药 ›› 2019, Vol. 47 ›› Issue (9): 990-993.doi: 10.11958/20192316

• 综述 • 上一篇    下一篇

Midkine在肿瘤发生发展中的作用和作为生物标志物的应用

侯莎莎,李宁,孟召伟△,谭建   

  1. 基金项目:国家自然科学基金资助项目(81571709) 作者单位:天津医科大学总医院核医学科(邮编300052) 作者简介:侯莎莎(1983),女,博士在读,主治医师,主要从事核医学肿瘤诊断和治疗的研究 △通讯作者 E-mail:jamesmencius@163.com
  • 收稿日期:2019-07-30 修回日期:2019-08-14 出版日期:2019-09-15 发布日期:2019-09-18
  • 通讯作者: 孟召伟 E-mail:jamesmencius@163.com
  • 基金资助:
    Midkine拮抗核素碘131治疗耐药的通路机制研究

The role of Midkine in tumor development and its application as biomarkers

HOU Sha-sha, LI Ning, MENG Zhao-wei△, TAN Jian   

  1. Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China △Corresponding Author E-mail:jamesmencius@163.com
  • Received:2019-07-30 Revised:2019-08-14 Published:2019-09-15 Online:2019-09-18
  • Supported by:
    Pathway mechanistic study of midkine against radioactive isotope iodine 131 therapeutic resistance

摘要: 中期因子(MK)是一种新的肝素结合生长因子,因起初在孕中期小鼠胚胎肾脏发现其大量表达而得名。 MK在多种恶性肿瘤组织中高表达,且在肿瘤的发生、发展及转移中发挥着重要作用,可促进肿瘤细胞增殖、迁移和 肿瘤血管生成等过程,并影响肿瘤患者的预后,而在正常组织或癌旁组织中低表达甚至不可测。值得注意的是,MK 是一种可溶性细胞因子,在血液和其他体液,如尿液和脑脊液中升高非常明显,这使得其成为一种相对方便、可获 得、非侵入性和廉价的生物标志物,可用于人群筛查和早期疾病检测。目前MK已被证明是一种能够显著提高癌症 检测、管理和治疗水平的生物标志物。本文就MK与肿瘤发生发展、预后及在生物标志物中的应用的研究现状进行 综述。

关键词: 肿瘤, 细胞因子类, 中期因子, 发生发展, 标志物

Abstract: Midkine (MK) is a new heparin-binding growth factor. It was named after the initial expression of mouse embryonic kidneys in the second trimester of pregnancy. MK is highly expressed in a variety of malignant tumor tissues and plays an important role in the occurrence, development and metastasis of tumors, which can promote the process of cancer cell proliferation, migration and tumor angiogenesis, and affect the prognosis of tumor patients, while its expression is low or even undetectable in normal tissues or adjacent tissues. Significantly, because it is a soluble cytokine, the elevated MK is readily apparent in the blood and other body fluids such as urine and cerebrospinal fluid (CSF), making MK a relatively convenient, accessible, non-invasive and inexpensive biomarker for population screening and early disease detection. MK has already proven to be a biomarker that can significantly improve detection, management and treatment of cancer. This article reviews the research status of MK and tumor development, prognosis and its application in biomarkers.

Key words: neoplasms, cytokines, midkine, development, marker